192 related articles for article (PubMed ID: 33684691)
21. Structure-based discovery of new selective small-molecule sirtuin 5 inhibitors.
Liu S; Ji S; Yu ZJ; Wang HL; Cheng X; Li WJ; Jing L; Yu Y; Chen Q; Yang LL; Li GB; Wu Y
Chem Biol Drug Des; 2018 Jan; 91(1):257-268. PubMed ID: 28756638
[TBL] [Abstract][Full Text] [Related]
22. Nitro-fatty acids as activators of hSIRT6 deacetylase activity.
Carreño M; Bresque M; Machado MR; Santos L; Durán R; Vitturi DA; Escande C; Denicola A
J Biol Chem; 2020 Dec; 295(52):18355-18366. PubMed ID: 33122195
[TBL] [Abstract][Full Text] [Related]
23. Biological and catalytic functions of sirtuin 6 as targets for small-molecule modulators.
Klein MA; Denu JM
J Biol Chem; 2020 Aug; 295(32):11021-11041. PubMed ID: 32518153
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine.
Song N; Guan X; Zhang S; Wang Y; Wang X; Lu Z; Chong D; Wang JY; Yu R; Yu W; Jiang T; Gu Y
Cell Death Dis; 2023 Aug; 14(8):499. PubMed ID: 37542062
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic activity of new acetoxycoumarin derivatives in cancer cell lines.
Musa MA; Badisa VL; Latinwo LM; Cooperwood J; Sinclair A; Abdullah A
Anticancer Res; 2011 Jun; 31(6):2017-22. PubMed ID: 21737617
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and biological screening of a series of pyrazolo [1,5-a]quina-zoline derivatives as SIRT6 activators.
Zhang Z; Sun W; Zhang G; Fang Z; Chen X; Li L
Eur J Pharm Sci; 2023 Jun; 185():106424. PubMed ID: 36918058
[TBL] [Abstract][Full Text] [Related]
27. Sirtuin 6, a possible therapeutic target for type 2 diabetes.
Bae EJ
Arch Pharm Res; 2017 Dec; 40(12):1380-1389. PubMed ID: 29177584
[TBL] [Abstract][Full Text] [Related]
28. Emerging role of sirtuins in breast cancer metastasis and multidrug resistance: Implication for novel therapeutic strategies targeting sirtuins.
Sinha S; Sharma S; Vora J; Shrivastava N
Pharmacol Res; 2020 Aug; 158():104880. PubMed ID: 32442721
[TBL] [Abstract][Full Text] [Related]
29. Fluvastatin activates sirtuin 6 to regulate sterol regulatory element-binding proteins and AMP-activated protein kinase in HepG2 cells.
Kim JH; Lee JM; Kim JH; Kim KR
Biochem Biophys Res Commun; 2018 Sep; 503(3):1415-1421. PubMed ID: 30078674
[TBL] [Abstract][Full Text] [Related]
30. Docking and binding free energy calculations of sirtuin inhibitors.
Karaman B; Sippl W
Eur J Med Chem; 2015 Mar; 93():584-98. PubMed ID: 25748123
[TBL] [Abstract][Full Text] [Related]
31. Novel p-Functionalized Chromen-4-on-3-yl Chalcones Bearing Astonishing Boronic Acid Moiety as MDM2 Inhibitor: Synthesis, Cytotoxic Evaluation and Simulation Studies.
Bhatia RK; Singh L; Garg R; Kaur M; Yadav M; Madan J; Kancherla S; Pissurlenkar RRS; Coutinho EC
Med Chem; 2020; 16(2):212-228. PubMed ID: 31146672
[TBL] [Abstract][Full Text] [Related]
32. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
Yang L; Ma X; Yuan C; He Y; Li L; Fang S; Xia W; He T; Qian S; Xu Z; Li G; Wang Z
Eur J Med Chem; 2017 Jul; 134():230-241. PubMed ID: 28415012
[TBL] [Abstract][Full Text] [Related]
33. Novel 3-(2-(3-methyl-5-substituted-phenyl-4,5-dihydropyrazol-1-yl)-2-oxoethoxy)-2-substituted-phenyl-4H-chromen-4-one: synthesis and anticancer activity.
Liu XH; Li J; Wu FR; Song BA; Bhadury PS; Shi L
Med Chem; 2011 Nov; 7(6):605-10. PubMed ID: 22313300
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel and selective SIRT6 inhibitors.
Parenti MD; Grozio A; Bauer I; Galeno L; Damonte P; Millo E; Sociali G; Franceschi C; Ballestrero A; Bruzzone S; Del Rio A; Nencioni A
J Med Chem; 2014 Jun; 57(11):4796-804. PubMed ID: 24785705
[TBL] [Abstract][Full Text] [Related]
35. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and Anticancer Study of Novel 4H-Chromen Derivatives.
Lu X; Dong G; Zheng Y; Zhang C; Qiu Y; Lua T; Zhou X
Anticancer Agents Med Chem; 2017; 17(8):1070-1083. PubMed ID: 27141877
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and characterization of a SIRT6 open tubular column: predicting deacetylation activity using frontal chromatography.
Singh N; Ravichandran S; Norton DD; Fugmann SD; Moaddel R
Anal Biochem; 2013 May; 436(2):78-83. PubMed ID: 23376017
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
[TBL] [Abstract][Full Text] [Related]
39. A FRET-based assay for screening SIRT6 modulators.
Li Y; You L; Huang W; Liu J; Zhu H; He B
Eur J Med Chem; 2015; 96():245-9. PubMed ID: 25884115
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
